MaxCyte Elects New Directors, Stockholder Proposals Approved
Ticker: MXCT · Form: 8-K · Filed: Jun 12, 2024 · CIK: 1287098
Sentiment: neutral
Topics: board-of-directors, annual-meeting, governance
Related Tickers: MXCT
TL;DR
MaxCyte added 2 directors and shareholders approved everything at the annual meeting.
AI Summary
MaxCyte, Inc. announced on June 11, 2024, the election of Dr. David L. Brown and Ms. Jennifer L. D. Sim as Class II directors to its Board of Directors, effective immediately. Additionally, the company reported on the outcome of its 2024 Annual Meeting of Stockholders, where all proposals, including the election of directors and the ratification of its independent registered public accounting firm, were approved.
Why It Matters
The election of new directors can signal strategic shifts or enhanced governance for MaxCyte, while the approval of stockholder proposals indicates alignment between management and its investors.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance matters such as director elections and stockholder meeting outcomes, with no immediate financial or operational risks disclosed.
Key Players & Entities
- MaxCyte, Inc. (company) — Registrant
- Dr. David L. Brown (person) — Elected Class II Director
- Ms. Jennifer L. D. Sim (person) — Elected Class II Director
- June 11, 2024 (date) — Effective date of director elections
- 2024 Annual Meeting of Stockholders (event) — Meeting where proposals were voted on
FAQ
Who were the individuals elected as Class II directors?
Dr. David L. Brown and Ms. Jennifer L. D. Sim were elected as Class II directors.
When were the new directors' elections effective?
The elections of Dr. David L. Brown and Ms. Jennifer L. D. Sim were effective immediately as of June 11, 2024.
What was the outcome of the 2024 Annual Meeting of Stockholders?
All proposals presented at the 2024 Annual Meeting of Stockholders, including the election of directors and the ratification of the independent registered public accounting firm, were approved.
What is MaxCyte, Inc.'s state of incorporation?
MaxCyte, Inc. is incorporated in Delaware.
What is MaxCyte, Inc.'s fiscal year end?
MaxCyte, Inc.'s fiscal year ends on December 31.
Filing Stats: 703 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-12 16:45:21
Key Financial Figures
- $0.01 — ge on which registered Common Stock, $0.01 par value MXCT The Nasdaq Stock Mar
Filing Documents
- mxct-20240611x8k.htm (8-K) — 55KB
- mxct-20240611xex10d1.htm (EX-10.1) — 212KB
- 0001558370-24-009097.txt ( ) — 434KB
- mxct-20240611.xsd (EX-101.SCH) — 3KB
- mxct-20240611_lab.xml (EX-101.LAB) — 16KB
- mxct-20240611_pre.xml (EX-101.PRE) — 10KB
- mxct-20240611x8k_htm.xml (XML) — 5KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. During the Annual Meeting, the Company's stockholders considered three proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal 1 - Election of directors: Nominee For Withhold Broker Non-Votes Will Brooke 68,727,229 1,026,170 12,060,733 John Johnston 68,991,928 761,471 12,060,733 Richard Douglas 48,055,363 21,698,036 12,060,733 Proposal 2 - Approval of the Plan Amendment: Votes For Votes Against Abstentions Broker Non-Votes 58,665,618 10,758,144 329,637 12,060,733 Proposal 3 - Ratification of appointment of CohnReznick LLP as independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024: Votes For Votes Against Abstentions 81,711,923 7,327 94,882
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amended and Restated 2022 Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Date: June 12, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer